

Approved



Zimbabwe
Country Operational Plan
FY 2016



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
State		72,000		72,000	0	72,000
USAID		53,611,287	16,500,000	70,111,287	0	70,111,287
HHS/CDC	1,250,000	28,831,713		30,081,713	0	30,081,713
HHS/HRSA		525,000		525,000	0	525,000
State/AF		210,000		210,000	0	210,000
Total	1,250,000	83,250,000	16,500,000	101,000,000	0	101,000,000

Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency					On Hold Amount	Total
	State	HHS/CDC	HHS/HRSA	State/AF	USAID		
CIRC		3,614,526			9,528,844	0	13,143,370
HBHC	1,347	390,084		55,000	2,538,814	0	2,985,245
HKID	0				7,589,019	0	7,589,019
HLAB		84,881			135,200	0	220,081
HMBL		0				0	0
HMIN		0				0	0
HTXD		0			21,971,822	0	21,971,822
HTXS		12,341,316	400,000		14,977,286	0	27,718,602
HVAB	776					0	776
HVCT		3,701,688			6,193,031	0	9,894,719
HVMS	41,853	4,472,928			2,870,020	0	7,384,801
HVOP	13,779	14,146		120,000	748,533	0	896,458
HVSI		1,050,599		10,000	358,404	0	1,419,003

Approved



HVTB		897,977			740,586	0	1,638,563
MTCT		1,013,684			296,085	0	1,309,769
OHSS	14,245	263,661		25,000	512,876	0	815,782
PDCS		482,672			233,875	0	716,547
PDTX		1,753,551	125,000		1,416,892	0	3,295,443
	72,000	30,081,713	525,000	210,000	70,111,287	0	101,000,000



Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	2,875,369	0
HKID	7,192,355	0
HVTB	1,289,989	0
PDCS	666,321	0
Total Technical Area Planned Funding:	12,024,034	0

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	135,200	0
HVSI	349,572	0
OHSS	726,062	0
Total Technical Area Planned Funding:	1,210,834	0

Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
CIRC	12,704,610	0
HMIN	0	
HVCT	9,665,677	0
HVOP	662,635	0
MTCT	1,087,100	0
Total Technical Area Planned Funding:	24,120,022	0

Approved



Technical Area: Treatment

Budget Code	Budget Code Planned Amount	On Hold Amount
HTXD	21,971,822	0
HTXS	26,568,513	0
PDTX	3,102,505	0
Total Technical Area Planned Funding:	51,642,840	0



Technical Area Summary Indicators and Targets

Indicator Number	Label	2017
PMTCT_STAT_TA	PMTCT_STAT_TA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (TA)	n/a
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	204,487
	Number of new ANC and L&D clients	213,746
	By: Known positives at entry	17,887
	By: Number of new positives identified	18,624
	Sum of Positives Status disaggregates	36,511
	Required only for DREAMS countries - By known positives: <15	368
	Required only for DREAMS countries - By known positives: 15-19	765
	Required only for DREAMS countries - By known positives: 20-24	2,189
	Required only for DREAMS countries - By new positives: <15	364
	Required only for DREAMS countries - By new positives: 15-19	1,552
	Required only for DREAMS countries - By new positives: 20-24	3,414



	Required only for DREAMS countries - Denominator: <15	5,034
	Required only for DREAMS countries - Denominator: 15-19	19,189
	Required only for DREAMS countries - Denominator: 20-24	52,730
	Required only for DREAMS countries - Denominator: 25-49	123,907
	Required only for DREAMS countries - Denominator: 50+	5,029
	Required only for DREAMS countries - By known positives: 25-49	12,831
	Required only for DREAMS countries - By known positives: 50+	1,110
	Required only for DREAMS countries - By new positives: 25-49	11,761
	Required only for DREAMS countries - By new positives: 50+	1,092
	By Age (DREAMS SNU ONLY): <15	4,728
	By Age (DREAMS SNU ONLY): 15-19	18,324
	By Age (DREAMS SNU ONLY): 20-24	50,268
	By Age (DREAMS SNU ONLY): 25-49	118,444
	By Age (DREAMS SNU ONLY): 50+	4,731
PMTCT_ART_TA	PMTCT_ART_TA Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	n/a



	Number of HIV-positive pregnant women who	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	204,487
	New on ART	16,408
	Already on ART at beginning of current pregnancy	16,736
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	252,847
	By Age: 0-60 days	0
	By Age: 2 months - 9 years	0
	By Age: 10-14	73,920
	By Age: 15-19	95,916
	By Age: 20-24	40,364
	By Age: 25-29	29,987
	By Age: 30-49	10,865
	By Age: 50+	1,795
	Sum of age disaggregates (Prior to FY15)	211,995
	Sum of age disaggregates (FY15-Current)	252,847
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	
	By HIV status: Number of clients with undocumented/indeterminate	



	HIV status or not tested for HIV at site	
	By circumcision technique: Surgical VMMC	161,053
	By circumcision technique: Device-based VMMC	91,794
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	
	By follow-up status: Number of device based circumcision clients who returned at least once for follow-up care within 14 days of device placement	
PrEP_NEW_DSD	PrEP_NEW_DSD Number of individuals who have received antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV infection in the reporting period.	n/a
	Number of individuals who have received antiretroviral preexposure	871
	Male 10-14	
	Male 15-19	0
	Male 20-24	0
	Male 25-49	0
	Male 50+	0
	Female 10-14	
	Female 15-19	287
	Female 20-24	584
	Female 25-49	0
Female 50+	0	
PP_PREV_DSD	PP_PREV_DSD Percentage of the	n/a



	target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	83,053
	Total number of people in the target population	243,224
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Denominator: Age/sex: 10-14 Male	
	Denominator: Age/sex: 15-19 Male	
	Denominator: Age/sex: 20-24 Male	
	Denominator: Age/sex: 25-49 Male	
	Denominator: Age/sex: 50+ Male	
	Denominator: Age/sex: 10-14 Female	
	Denominator: Age/sex: 15-19 Female	
	Denominator: Age/sex: 20-24 Female	



	Denominator: Age/sex: 25-49 Female	
	Denominator: Age/sex: 50+ Female	
	Service: PP known positive	
	Service: PP tested or referred for testing as part of program	
	New Client: New beneficiary	
	New Client: Returning Beneficiary	
	Aggregated Age/sex: <15 Male	
	Aggregated Age/sex: 15+ Male	
	Aggregated Age/sex: <15 Female	
	Aggregated Age/sex: 15+ Female	83,053
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	12,593
	Total estimated number of key population in the catchment area	17,320
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0



	<p>By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	<p>1,662</p>
	<p>By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	<p>0</p>
	<p>By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	<p>0</p>
	<p>By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	<p>10,931</p>
	<p>By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual</p>	<p>0</p>



	and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	0
	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	2,078
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	0
	By key population type:	0



	Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	15,242
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	0
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	0
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	0
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: REturniong beneficiary within the current report period	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received	1,288,365



	their test results during the past 12 months	
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	15,285
	Age/sex: 15-19 Male	30,287
	Age/sex: 20-24 Male	66,344
	Age/sex: 25-49 Male	171,757
	Age/sex: 50+ Male	24,832
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	13,238
	Age/sex: 15-19 Female	38,588
	Age/sex: 20-24 Female	84,956
	Age/sex: 25-49 Female	204,244
	Age/sex: 50+ Female	30,522
	Test Result by Age and Sex: Positive: 10-14 Male	1,685
	Test Result by Age and Sex: Positive: 15-19 Male	3,068
	Test Result by Age and Sex: Positive: 20-24 Male	6,503
	Test Result by Age and Sex: Positive: 25-49 Male	18,866
	Test Result by Age and Sex: Positive: 50+ Male	2,823
	Test Result by Age and Sex: Positive: 10-14 Female	1,537
	Test Result by Age and Sex: Positive: 15-19 Female	3,880
	Test Result by Age and Sex: Positive: 20-24 Female	8,203
	Test Result by Age and Sex: Positive: 25-49 Female	22,368
	Test Result by Age and Sex:	3,245



	Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	78,265
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	449,058
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	79,306
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	630,295
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age	



	and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age and Sex: Positive <15 Male	6,335
	Test Result by Aggregated Age and Sex: Positive 15+ Male	46,337
	Test Result by Aggregated Age and Sex: Positive <15 Female	6,366
	Test Result by Aggregated Age and Sex: Positive 15+ Female	64,454
	Test Result by Age: Positive: <1	388
	Test Result by Age: Positive: 1-9	2,829
	Age/sex: <1	3,875
	Age/sex: 1-9	30,758
	Service Delivery Point (Community): Index testing	125,325
	Service Delivery Point (Community): Homebased testing	0
	Service Delivery Point (Community): Mobile testing	360,310
	Service Delivery Point (Community): Other	22,116
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community)	



	by Age: <15 mobile testing	
	Service Delivery Point (Community)	
	by Age: 15+ mobile testing	
	Service Delivery Point (Community)	
	by Age: <15 other	
	Service Delivery Point (Community)	
	by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	40,167
	Service Delivery Point (Facility): Outpatient	311,719
	Service Delivery Point (Facility): Pediatric	26,523
	Service Delivery Point (Facility): Malnutrition facilities	662
	Service Delivery Point (Facility): Other PITC	48,718
	Service Delivery Point (Facility): VCT	81,621
	Service Delivery Point (Facility): VMMC	308
	Service Delivery Point (Facility): PMTCT	22,083
	Service Delivery Point (Facility): TB Clinics	15,671
	Service Delivery Point (Facility): Index testing	4,480
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by	



	Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatroc	
	Service Delivery Point (Facility) by Age: >15 Pediatroc	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
HTC_TST_TA	Number of individuals who received	1,256,289



	T&C services for HIV and received their test results during the past 12 months	
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	57,778
	Age/sex: 15-19 Male	27,250
	Age/sex: 20-24 Male	32,391
	Age/sex: 25-49 Male	88,656
	Age/sex: 50+ Male	19,630
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	63,060
	Age/sex: 15-19 Female	41,681
	Age/sex: 20-24 Female	55,217
	Age/sex: 25-49 Female	110,832
	Age/sex: 50+ Female	22,347
	Test Result by Age and Sex: Positive: 10-14 Male	2,513
	Test Result by Age and Sex: Positive: 15-19 Male	2,257
	Test Result by Age and Sex: Positive: 20-24 Male	2,659
	Test Result by Age and Sex: Positive: 25-49 Male	6,940
	Test Result by Age and Sex: Positive: 50+ Male	1,832
	Test Result by Age and Sex: Positive: 10-14 Female	2,756
	Test Result by Age and Sex: Positive: 15-19 Female	3,245
	Test Result by Age and Sex: Positive: 20-24 Female	4,967
	Test Result by Age and Sex: Positive: 25-49 Female	9,953



	Test Result by Age and Sex: Positive: 50+ Female	2,104
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: <1 Female	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	115,091
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	302,859
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	122,376
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	496,629



Test Result by Aggregated Age and Sex: Negative <15 Male	
Test Result by Aggregated Age and Sex: Negative 15+ Male	
Test Result by Aggregated Age and Sex: Negative <15 Female	
Test Result by Aggregated Age and Sex: Negative 15+ Female	
Test Result by Aggregated Age and Sex: Positive <15 Male	5,844
Test Result by Aggregated Age and Sex: Positive 15+ Male	28,373
Test Result by Aggregated Age and Sex: Positive <15 Female	6,276
Test Result by Aggregated Age and Sex: Positive 15+ Female	50,210
Test Result by Age: Positive: <1	602
Test Result by Age: Positive: 1-9	4,083
Age/sex: <1	15,405
Age/sex: 1-9	95,370
Service Delivery Point (Community): Index testing	0
Service Delivery Point (Community): Homebased testing	0
Service Delivery Point (Community): Mobile testing	0
Service Delivery Point (Community): Other	21,973
Service Delivery Point (Community) by Age: <15 index testing	
Service Delivery Point (Community) by Age: 15+ index testing	
Service Delivery Point (Community) by Age: <15 homebased testing	



	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	66,537
	Service Delivery Point (Facility): Outpatient	620,048
	Service Delivery Point (Facility): Pediatric	196,284
	Service Delivery Point (Facility): Malnutrition facilities	6,338
	Service Delivery Point (Facility): Other PITC	33,606
	Service Delivery Point (Facility): VCT	113,347
	Service Delivery Point (Facility): VMMC	5
	Service Delivery Point (Facility): PMTCT	182,104
	Service Delivery Point (Facility): TB Clinics	6,249
	Service Delivery Point (Facility): Index testing	11,476
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	



	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatroc	
	Service Delivery Point (Facility) by Age: >15 Pediatroc	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	



	Service Delivery Point (Facility) by Age: >15 Index testing	
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	n/a
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	180
	Total number of registered new and relapsed TB cases, during the reporting period.	220
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: Number of registered new and relapsed TB cases with	



	documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	



	reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	4
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	46
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	12
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	118
	Result: Known HIV positive at service entry	
	Result: New HIV positive	
	Result: HIV Negative	
	Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 10-14 (Denominator: Total number of	



	registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 50+	



	(Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
TB_STAT_TA	TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.	n/a
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	18,449
	Total number of registered new and relapsed TB cases, during the reporting period.	18,790
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	



	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered	



	new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	741
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	7,812
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	719
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with	6,536



	documented HIV status, during the reporting period)	
	Result: Known HIV positive at service entry	
	Result: New HIV positive	
	Result: HIV negative	
	Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 10-14	



	(Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	381,733
	Age/Sex: 10-14 Male	
	Age/Sex: 15-17 Male	
	By: Age/sex: Male 18-24	
	By: Age/sex: Male 25+	
	Age/Sex: 18+ Male	16,147
	Age/Sex: 10-14 Female	
	Age/Sex: 15-17 Female	
	By: Age/sex: 18-24 Female	
	By: Age/sex: 25+ Female	
	Age/Sex: 18+ Female	40,512
	Sum of Age/Sex disaggregates	56,659
	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	0
Required only for DREAMS	3,643	



	countries - By service, age and sex: Education Support Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	3,697
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	629
	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	0
	Required only for DREAMS countries - By service, age and sex: Education Support Male <1	0
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	3,083
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	1,457
	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	68
	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	0
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1	0
	Required only for DREAMS	0



	countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	0
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	631
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	30,324
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1	0
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	0
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	0
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	137
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	7,991



	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1	0
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	3,804
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	2,283
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	761
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+	0
	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1	0
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	0
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	0
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	0
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+	0
	Required only for DREAMS countries - By service, age and	0



	sex: Economic Strengthening Female <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	0
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	0
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	4,910
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	31,488
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1	0
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	0
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	0
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	1,455
	Required only for DREAMS	8,058



	countries - By service, age and sex: Economic Strengthening Male 25+	
	Required only for DREAMS countries - By service, age and sex: Other Services Female <1	3,976
	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	62,728
	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	25,971
	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	577
	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	4,696
	Required only for DREAMS countries - By service, age and sex: Other Services Male <1	4,027
	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	59,378
	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	21,932
	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	354
	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	329
	Age/Sex: <1	
	Age/Sex: 1-9	



	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	4,278
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-9	0
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Male 1-9	0
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-9	0
	Required only for DREAMS countries - By service, age and sex: Other Services Male 1-9	59,432
	Program Completion: Active	
	Program Completion: Graduation	
	Program Completion: Transferred	
	Program Completion: Exited without graduation	
	By Aggregated Age/Sex: <18 Male	144,435
	By Aggregated Age/Sex: 18+ Male	
	By Aggregated Age/Sex: <18 Female	150,564
	By Aggregated Age/Sex: 18+ Female	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	4,507
	Required only for DREAMS countries - By service, age and	0



	sex: Parenting/Caregiver Programs Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Female 1-9	0
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-9	0
	Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9	63,216
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	100
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	125
	Age/Sex: >1 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and	



	relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: The number of	



	registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented	0



	HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	40
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	60
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: >1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB	



	treatment during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	



	Age/Sex: Female 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15	



	(Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
TB_ART_TA	TB_ART_TA Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	10,031



	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	12,532
	Age/Sex: <1 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Numerator:	



	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented	



	HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	313
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4,030
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	291
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during	3,579



	the reporting period)	
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: <1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	



	<p>Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 25-49 (Denominator: The number of</p>	



	registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB	



	cases with documented HIV-positive status during TB treatment during the reporting period)	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	5,163
	Screened for TB by Age/Sex:<15 Male	0
	Screened for TB by Age/Sex: 15+ Male	1
	Screened for TB by Age/Sex:<15 Female	0
	Screened for TB by Age/Sex: 15+ Female	50
	Screen Result: Screened Positive for TB	51
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	51
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	51
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	51
	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0



TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	888,805
	Screened for TB by Age/Sex: <15 Male	24,475
	Screened for TB by Age/Sex: 15+ Male	240,011
	Screened for TB by Age/Sex: <15 Female	25,179
	Screened for TB by Age/Sex: 15+ Female	437,972
	Screen Results: Screened Positive for TB	223,747
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	161,115
	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	145,737
	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	6,337
[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	8,307	
PMTCT_EID_TA	PMTCT_EID_TA Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (TA)	n/a



	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	
	By infants who received a virologic test within 2 months of birth	25,798
	By infants who received their first virologic HIV test between 2 and 12 months of age	7,338
	Sum of Infant Age disaggregates	33,136
	By infants with a positive virologic test result within 12 months of birth	
	Number of infants with a positive virological test result within 2 months of birth	602
	Number of infants with a negative virological test result within 2 months of birth	
	Number of infants with a positive virological test result between 2 and 12 months of birth	
	Number of infants with a negative virological test result between 2 and 12 months of birth	
	Number of infants with a positive virological test result within 12 months of birth	379
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	158,636
	Age/Sex: 15-19 Male	1,039



	Age/Sex: 15-19 Female	3,589
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	8,403
	Aggregated Age/Sex: 15+ Male	46,147
	Aggregated Age/Sex: <15 Female	8,499
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	91,969
	Sum of Aggregated Age/Sex <15	16,902
	Sum of Aggregated Age/Sex 15+	138,116
	Sum of Aggregated Age/Sex disaggregates	155,018
	Age/Sex: <1	135
	Age/Sex: <1-9	671
	Age/Sex: 10-14 Male	165
	Age/Sex: 10-14 Female	177
	Aggregated Age/Sex: 1-14 Male	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	2,217
	Age/Sex: 25-49 Male	21,667
	Age/Sex: 50+ Male	3,888
	Age/Sex: 20-24 Female	10,336
	Age/Sex: 25-49 Female	43,380
	Age/Sex: 50+ Female	4,689
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	861,996
	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-14 Male	



Age/Sex: 15-19 Male	5,278
Age/Sex: 20+ Male	
Age/Sex: <1 Female	
Age/Sex: 1-4 Female	
Age/Sex: 5-14 Female	
Age/Sex: 15-19 Female	18,170
Age/Sex: 20+ Female	
Sum of Age/Sex disaggregations	23,448
Aggregated Age/Sex: <1 Male	
Aggregated Age/Sex: <1 Female	
Aggregated Age/Sex: <15 Male	42,901
Aggregated Age/Sex: 1-14 Male	
Aggregated Age/Sex: 15+ Male	255,279
Aggregated Age/Sex: <15 Female	42,981
Aggregated Age/Sex: 1-14 Female	
Aggregated Age/Sex: 15+ Female	482,435
Sum of Aggregated Age/Sex <15	85,882
Sum of Aggregated Age/Sex 15+	737,714
Sum of Aggregated Age/Sex disaggregates	823,596
Age/Sex: <1	8,995
Age/Sex: 1-9	35,818
Age/Sex: 10-14 Male	9,484
Age/Sex: 10-14 Female	9,202
Sum of Aggregated Age/Sex (<1 and 1-14) <15	
Age/Sex: 20-24 Male	10,644
Age/Sex: 25-49 Male	125,327
Age/Sex: 50+ Male	22,474
Age/Sex: 20-24 Female	48,241
Age/Sex: 25-49 Female	238,393
Age/Sex: 50+ Female	24,683



TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	146,959
	By Age/Sex: <1	796
	By Age/Sex: 1-9	3,571
	By Age/Sex: 10-14 Male	978
	By Age/Sex: 15-19 Male	1,183
	By Age/Sex: 20-24 Male	2,919
	By Age/Sex: 25-49 Male	27,847
	By Age/Sex: 50+ Male	4,756
	By Age/Sex: 10-14 Female	973
	By Age/Sex: 15-19 Female	3,365
	By Age/Sex: 20-24 Female	9,755
	By Age/Sex: 25-49 Female	46,347
	By Age/Sex: 50+ Female	5,162
	Sum of Age/Sex disaggregates	103,285
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	5,282
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	39,565
	Aggregated Grouping by Age/Sex: <1 Female	
Aggregated Grouping by Age/Sex: <15 Female	5,363	
Aggregated Grouping by Age/Sex: 15+ Female	68,230	
Sum of Aggregated Age/Sex disaggregates	118,440	



	Pregnancy status	
	Breastfeeding status	
	Aggregated Grouping by Age/Sex: 1-14 Female	
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	109,875
	By Age/Sex: <1	
	By Age/Sex: 1-9	4,799
	By Age/Sex: <1 Male	
	By Age/Sex: 1-4 Male	
	By Age/Sex: 5-9 Male	
	By Age/Sex: 10-14 Male	1,277
	By Age/Sex: 15-19 Male	800
	By Age/Sex: 20-24 Male	1,584
	By Age/Sex: 25-49 Male	18,697
	By Age/Sex: 50+ Male	3,468
	By Age/Sex: <1 Female	
	By Age/Sex: 1-4 Female	
	By Age/Sex: 5-9 Female	
	By Age/Sex: 10-14 Female	1,265
	By Age/Sex: 15-19 Female	2,240
	By Age/Sex: 20-24 Female	5,954
	By Age/Sex: 25-49 Female	28,592
	By Age/Sex: 50+ Female	2,930
	Sum of Age/Sex disaggregates	66,807
	Aggregated Grouping by Age: <1	1,168
Aggregated Grouping by Age: <1 Male		
Aggregated Grouping by Age/Sex: <15 Male	7,889	
Aggregated Grouping by Age/Sex: 1-14 Male		



	Aggregated Grouping by Age/Sex: 15+ Male	34,029
	Aggregated Grouping by Age: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	8,001
	Aggregated Grouping by Age/Sex: 1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	55,677
	Sum of Aggregated Age/Sex disaggregates	105,596
	Pregnancy status	
	Breastfeeding status	
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	5,163
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	5,735
	Numerator: Indication: Routine	4,389
	Numerator: Indication: Targeted	774
	Numerator: Preg/BF by Indication:	



	Pregnant Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication:	



	1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by	



	Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Indication: Routine	4,875
	Denominator: Indication: Targeted	860
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by	



	Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex	



	by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator Aggregated Age/Sex: <15 Male	0
	Numerator Aggregated Age/Sex: 15+ Male	207
	Numerator Aggregated Age/Sex: <15 Female	0
	Numerator Aggregated Age/Sex: 15+ Female	4,956
	Denominator Aggregated Age/Sex: <15 Male	0
	Denominator Aggregated Age/Sex: 15+ Male	229
	Denominator Aggregated Age/Sex: <15 Female	0
	Denominator Aggregated Age/Sex: 15+ Female	5,506
TX_PVLS_TA	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed	136,600



	viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	195,360
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication:	



	20-24 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator: Aggregate Age/Sex by	



	Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Indication: Routine	25,576
	Numerator: Indication: Targeted	96,649
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Indication: Routine	35,683
	Denominator: Indication: Targeted	159,677
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by	



	Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex	



	by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Numerator Aggregated Age/Sex: <15 Male	3,655
	Numerator Aggregated Age/Sex: 15+ Male	42,968
	Numerator Aggregated Age/Sex: <15 Female	3,855
	Numerator Aggregated Age/Sex: 15+ Female	58,811
	Denominator Aggregated Age/Sex: <15 Male	5,272
	Denominator Aggregated Age/Sex: 15+ Male	61,605
	Denominator Aggregated Age/Sex:	5,550



	<15 Female	
	Denominator Aggregated Age/Sex: 15+ Female	84,377
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,394
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,439
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	15
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who	74



	are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	107
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	15
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	0
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	164
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	764
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,093
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	164
	Age/Sex: >1 (Denominator: Total	0



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	14
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and	75



	those lost to follow-up)	
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	109
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	16
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	167
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated	778



	ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,114
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	167
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and	



	those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	211
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,183



	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	214
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,225
TX_RET_TA	TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a



	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	143,201
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	154,879
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	71
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,210
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,330
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,226
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	594
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	18,814
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,871



	Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,556
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,443
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,272
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	38,621
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11,750
	Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	77
	Age/Sex: 1-9 (Denominator: Total number of adults and children who	3,456



	initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,443
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,315
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	647
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and	20,330



	those lost to follow-up)	
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,437
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,694
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,576
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,510
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated	41,817



	ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12,688
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and	



	those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,752
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	46,954
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,097
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	85,016
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,170



	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	50,774
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,492
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	91,948
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	0
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	0



	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
	CD4: Number of laboratories that perform this testing	6
	CD4: Number of laboratories that participate in this PT program	6
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	6
	Early infant diagnostics: Number of laboratories that perform this testing	3
	Early infant diagnostics: Number of laboratories that participate in this PT program	3
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	3
	HIV viral load: Number of laboratories that perform this testing	6
	HIV viral load: Number of laboratories that participate in this PT program	6
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	6
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	0
	TB diagnostics (AFB microscopy):	0



	Number of laboratories that participate in this PT program	
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	5
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	5
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	5
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	0
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	0
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
LAB_PT_TA	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	68



	CD4: Number of laboratories that participate in this PT program	85
	CD4: Number of laboratories that perform this testing	85
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
	Early infant diagnostics: Number of laboratories that participate in this PT program	0
	Early infant diagnostics: Number of laboratories that perform this testing	0
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	720
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	810
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	1,864
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
	HIV viral load: Number of laboratories that participate in this PT program	0
	HIV viral load: Number of laboratories that perform this testing	0
	TB diagnostics (AFB microscopy):	0



	Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	0
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	0
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	44
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	55
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	120
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	0
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	0
INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	
	Number of HIV Test Kits purchased	
	Number of HIV CD4 Reagents	

Approved



	purchased	
	Number of Condoms purchased	
	Number of HIV Viral Load Reagents purchased	214,000
	Number of HIV ARVs purchased	192,989
	Number of Second Line HIV ARVs purchased	
	HIV Test Kits: Dollars planned (COP)/ spent (Actual)	
	HIV CD4 Tests: Dollars planned (COP)/ spent (Actual)	
	HIV Viral Load: Dollars planned (COP)/ spent (Actual)	3,000,000
	Condoms: Dollars planned (COP)/ spent (Actual)	
	HIV ARVs: Dollars planned (COP)/ spent (Actual)	



Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
12862	University of Zimbabwe	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12933	Population Services International	NGO	U.S. Agency for International Development	GHP-State, GHP-USAID	11,027,933
13152	University of Zimbabwe	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13173	Biomedical Research and Training Institute	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13889	World Education's Batwana Initiative	Implementing Agency	U.S. Agency for International Development	GHP-USAID	2,620,718
13890	Organisation for	Implementing	U.S. Agency for	GHP-State,	9,907,471



	Public Health Interventions and Development	Agency	International Development	GHP-USAID	
13911	New York AIDS Institute	Other USG Agency	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	0
16515	ITECH	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	13,029,528
16804	ITECH	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,329,239
16806	Zimbabwe Association of Church Hospitals	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,204,772
17013	Department of State/AF - Public Affairs Section	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	100,000
17015	State/AF Ambassador's	Implementing Agency	U.S. Department of State/Bureau of	GHP-State	60,000



	PEPFAR Small Grants Program		African Affairs		
17475	Association of Public Health Laboratories	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,500,000
17476	University of Zimbabwe	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	200,000
17534	Mavambo Orphan Care (MOC)	NGO	U.S. Agency for International Development	GHP-State	1,042,059
17541	Family AIDS Care Trust (FACT) Mutare	NGO	U.S. Agency for International Development	GHP-State	2,487,519
17546	Hospice and Palliative Care Association of Zimbabwe	NGO	U.S. Agency for International Development	GHP-State	1,042,059
17578	FHI 360	NGO	U.S. Agency for International Development	GHP-State	5,558,697
17771	International Union Against TB and Lung Disease	NGO	U.S. Agency for International Development	GHP-USAID	0
17882	Research Triangle International	Private Contractor	U.S. Department of Health and Human	GHP-State	858,289



			Services/Centers for Disease Control and Prevention		
17883	International Center for AIDS Care and Treatment Programs, Columbia University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	650,000
17884	Health Research Inc./New York State Department of Health	Other USG Agency	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	525,000
17885	Biomedical Research and Training Institute	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	500,000
17887	John Snow Inc (JSI)	Implementing Agency	U.S. Agency for International Development	GHP-State	0
18138	Management Sciences for Health	NGO	U.S. Agency for International Development	GHP-State	63,403
18139	Southern Africa HIV and AIDS Information Dissemination Service (SAfAIDS)	NGO	U.S. Agency for International Development	GHP-State	0



18141	UNICEF	Multi-lateral Agency	U.S. Agency for International Development	GHP-State	0
18151	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	538,906
18174	Department of State/AF - Public Affairs Section	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	50,000
18286	TBD	TBD	Redacted	Redacted	Redacted
18353	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State	31,502,137



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 12862	Mechanism Name: Development of Health Leadership Capacity and Support of Human Resources for Health Systems in Zimbabwe
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Zimbabwe	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	12862		
Mechanism Name:	Development of Health Leadership Capacity and Support of Human Resources for Health Systems in Zimbabwe		
Prime Partner Name:	University of Zimbabwe		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12933	Mechanism Name: Strengthening Private Sector Health Care Services Project (SPSS)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 11,027,933	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 11,027,933	
Funding Source	Funding Amount
GHP-State	5,467,965
GHP-USAID	5,559,968

Cross-Cutting Budget Attribution(s)

Human Resources for Health	522,503
Key Populations: FSW	538,935
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Monitoring and evaluation of SW programs
Gender: Gender Equality	121,197
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Capacity building



Condom programming	329,956
Gender: GBV	10,902
Focus Area:	Post GBV Care
Sub Area:	Implementation

Budget Code Information

Mechanism ID:	12933		
Mechanism Name:	Strengthening Private Sector Health Care Services Project (SPSS)		
Prime Partner Name:	Population Services International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	199,883	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	7,181,771	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	2,132,196	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	542,635	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	971,448	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention	152,847



	program within the reporting period	
VMMC_CIRC_DSD	By Age: 0-60 days	0
VMMC_CIRC_DSD	By Age: 2 months - 9 years	0
VMMC_CIRC_DSD	By Age: 10-14	40,919
VMMC_CIRC_DSD	By Age: 15-19	55,916
VMMC_CIRC_DSD	By Age: 20-24	25,366
VMMC_CIRC_DSD	By Age: 25-29	22,989
VMMC_CIRC_DSD	By Age: 30-49	6,364
VMMC_CIRC_DSD	By Age: 50+	1,293
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	123,494
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	152,847
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	101,053
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	51,794
PrEP_NEW_DSD	Number of individuals who have received antiretroviral preexposure	871
PrEP_NEW_DSD	Male 15-19	0
PrEP_NEW_DSD	Male 20-24	0
PrEP_NEW_DSD	Male 25-49	0
PrEP_NEW_DSD	Male 50+	0
PrEP_NEW_DSD	Female 15-19	287
PrEP_NEW_DSD	Female 20-24	584
PrEP_NEW_DSD	Female 25-49	0
PrEP_NEW_DSD	Female 50+	0
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	12,593
KP_PREV_DSD	Total estimated number of key population in the catchment area	17,320
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on	0



	evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,662
KP_PREV_DSD	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	10,931
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0



KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	2,078
KP_PREV_DSD	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	15,242
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	439,949
HTC_TST_DSD	Age/sex: 10-14 Male	5,665
HTC_TST_DSD	Age/sex: 15-19 Male	19,792
HTC_TST_DSD	Age/sex: 20-24 Male	42,836
HTC_TST_DSD	Age/sex: 25-49 Male	121,024
HTC_TST_DSD	Age/sex: 50+ Male	15,988
HTC_TST_DSD	Age/sex: 10-14 Female	6,170



HTC_TST_DSD	Age/sex: 15-19 Female	22,891
HTC_TST_DSD	Age/sex: 20-24 Female	50,458
HTC_TST_DSD	Age/sex: 25-49 Female	126,621
HTC_TST_DSD	Age/sex: 50+ Female	16,665
HTC_TST_DSD	Sum of Age/Sex disaggregates	428,110
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	341
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	2,113
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	4,823
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	14,014
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	1,829
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	373
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	2,498
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	5,808
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	15,289
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	1,968
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	11,326
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	199,644
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	12,341
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	216,638
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	23,667
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	416,282
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	439,949
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	682
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	22,781
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	744
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+	25,558



	Female	
HTC_TST_DSD	Test Result by Age: Positive: <1	0
HTC_TST_DSD	Test Result by Age: Positive: 1-9	709
HTC_TST_DSD	Age/sex: <1	0
HTC_TST_DSD	Age/sex: 1-9	11,839
HTC_TST_DSD	Service Delivery Point (Community): Index testing	0
HTC_TST_DSD	Service Delivery Point (Community): Homebased testing	0
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	360,310
HTC_TST_DSD	Service Delivery Point (Community): Other	0
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	0
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	0
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	4,476
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	0
HTC_TST_DSD	Service Delivery Point (Facility): VCT	72,041
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	0
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	232
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	2,890
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	180
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	220
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	4
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	46
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	12

TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	118
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	100
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	125
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	40
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	60
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	5,163
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	0
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	1
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	0
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	50
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	51
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	51



TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	51
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	51
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	5,735
TX_CURR_DSD	Age/Sex: 15-19 Male	22
TX_CURR_DSD	Age/Sex: 15-19 Female	405
TX_CURR_DSD	Sum of age/sex disaggregates	427
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	0
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	340
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	0
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	5,395
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	0
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	5,735
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	5,735
TX_CURR_DSD	Age/Sex: <1	0
TX_CURR_DSD	Age/Sex: <1-9	0
TX_CURR_DSD	Age/Sex: 10-14 Male	0
TX_CURR_DSD	Age/Sex: 10-14 Female	0
TX_CURR_DSD	Age/Sex: 20-24 Male	120
TX_CURR_DSD	Age/Sex: 25-49 Male	170
TX_CURR_DSD	Age/Sex: 50+ Male	26
TX_CURR_DSD	Age/Sex: 20-24 Female	1,889
TX_CURR_DSD	Age/Sex: 25-49 Female	2,698
TX_CURR_DSD	Age/Sex: 50+ Female	405
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	8,006
TX_NEW_DSD	By Age/Sex: <1	0
TX_NEW_DSD	By Age/Sex: 1-9	0



TX_NEW_DSD	By Age/Sex: 10-14 Male	0
TX_NEW_DSD	By Age/Sex: 15-19 Male	20
TX_NEW_DSD	By Age/Sex: 20-24 Male	551
TX_NEW_DSD	By Age/Sex: 25-49 Male	3,907
TX_NEW_DSD	By Age/Sex: 50+ Male	245
TX_NEW_DSD	By Age/Sex: 10-14 Female	0
TX_NEW_DSD	By Age/Sex: 15-19 Female	247
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,149
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,640
TX_NEW_DSD	By Age/Sex: 50+ Female	247
TX_NEW_DSD	Sum of Age/Sex disaggregates	8,006
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	4,726
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	3,280
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	8,006
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	5,163
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	5,735
TX_PVLS_DSD	Numerator: Indication: Routine	4,389
TX_PVLS_DSD	Numerator: Indication: Targeted	774
TX_PVLS_DSD	Denominator: Indication: Routine	4,875
TX_PVLS_DSD	Denominator: Indication: Targeted	860
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	0
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	207
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	0
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	4,956
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	0



TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	229
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	0
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	5,506
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,394
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,439
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	0
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	0
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	0
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	15
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	74
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	107
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	15
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	0
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12	164



	months after initiating ART	
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	764
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,093
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	164
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	14
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	75



TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	109
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	16
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	167
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	778
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,114
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	167
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of	0



	adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	211
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,183
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	214
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,225

Implementing Mechanism Details

Mechanism ID: 13152	Mechanism Name: Surveys, Evaluation, Assessments, and Monitoring
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement



Prime Partner Name: University of Zimbabwe	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13152		
Mechanism Name:	Surveys, Evaluation, Assessments, and Monitoring		
Prime Partner Name:	University of Zimbabwe		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Approved



Treatment	HTXS	0	0
-----------	------	---	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13173	Mechanism Name: Strengthening Infection Control and Prevention in Health Care Facilities in Zimbabwe under the President's Emergency Plan for AIDS Relief (PEPFAR)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Biomedical Research and Training Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13173
Mechanism Name:	Strengthening Infection Control and Prevention in Health Care Facilities
Prime Partner Name:	in Zimbabwe under the President's Emergency Plan for AIDS Relief



(PEPFAR) Biomedical Research and Training Institute			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13889	Mechanism Name: Vana Batwana Zimbabwe Orphans and Vulnerable Children Project
Funding Agency: USAID	Procurement Type: Umbrella Agreement
Prime Partner Name: World Education 's Batwana Initiative	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 2,620,718	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,620,718	
Funding Source	Funding Amount
GHP-USAID	2,620,718

Cross-Cutting Budget Attribution(s)

Human Resources for Health	103,440
----------------------------	---------



Economic Strengthening	206,906
Education	206,906
Gender: GBV	354,834
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	206,906
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Implementation

Budget Code Information

Mechanism ID: 13889



Mechanism Name:	Vana Batwana Zimbabwe Orphans and Vulnerable Children Project		
Prime Partner Name:	World Education 's Batwana Initiative		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	2,620,718	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	96,498
OVC_SERV_DSD	Age/Sex: 18+ Male	486
OVC_SERV_DSD	Age/Sex: 18+ Female	9,834
OVC_SERV_DSD	Sum of Age/Sex disaggregates	10,320
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	1,048
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	1,027
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	663
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	253
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	7,505
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	427
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	1,745
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	7,769
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	74



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	412
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female <1	14
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	18,971
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	3,224
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male <1	11
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	18,517
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	2,056
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	1,314
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 1-9	19,642
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	40,226
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	45,952
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	1,363
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9	23,743

Implementing Mechanism Details

Mechanism ID: 13890	Mechanism Name: Families and Communities for the Elimination of Pediatric HIV (FACE-Pediatric HIV)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Organisation for Public Health Interventions and Development	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



Total All Funding Sources: 9,907,471	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 9,907,471	
Funding Source	Funding Amount
GHP-State	2,608,758
GHP-USAID	7,298,713

Cross-Cutting Budget Attribution(s)

Food and Nutrition: Policy, Tools, and Service Delivery	316,866
Gender: GBV	275,990
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Gender: Gender Equality	275,990
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Focus Area:	Promoting gender-related policies and laws that increase legal protection

Budget Code Information

Mechanism ID:	13890		
Mechanism Name:	Families and Communities for the Elimination of Pediatric HIV (FACE-Pediatric HIV)		
Prime Partner Name:	Organisation for Public Health Interventions and Development		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	326,747	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HVTB	498,126	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	69,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	2,269,416	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	211,009	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	5,366,106	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	1,166,567	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	104,098
PMTCT_ART_TA	New on ART	9,360
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	7,277
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	104,098
PMTCT_STAT_TA	Number of new ANC and L&D clients	108,006
PMTCT_STAT_TA	By: Known positives at entry	7,965
PMTCT_STAT_TA	By: Number of new positives identified	9,201
PMTCT_STAT_TA	Sum of Positives Status disaggregates	17,166
PMTCT_STAT_TA	Required only for DREAMS countries - By known	0



	positives: <15	
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 15-19	384
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 20-24	1,259
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: <15	7
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 15-19	1,180
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 20-24	2,538
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: <15	190
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 15-19	9,444
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 20-24	23,407
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 25-49	74,871
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 50+	94
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 25-49	6,333
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 50+	11
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 25-49	5,457
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 50+	9
PMTCT_STAT_TA	By Age (DREAMS SNUs ONLY): <15	180
PMTCT_STAT_TA	By Age (DREAMS SNUs ONLY): 15-19	9,103
PMTCT_STAT_TA	By Age (DREAMS SNUs ONLY): 20-24	22,586
PMTCT_STAT_TA	By Age (DREAMS SNUs ONLY): 25-49	72,145
PMTCT_STAT_TA	By Age (DREAMS SNUs ONLY): 50+	81



HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	157,513
HTC_TST_DSD	Age/sex: 10-14 Male	2,788
HTC_TST_DSD	Age/sex: 15-19 Male	7,627
HTC_TST_DSD	Age/sex: 20-24 Male	19,671
HTC_TST_DSD	Age/sex: 25-49 Male	31,362
HTC_TST_DSD	Age/sex: 50+ Male	4,735
HTC_TST_DSD	Age/sex: 10-14 Female	3,603
HTC_TST_DSD	Age/sex: 15-19 Female	9,634
HTC_TST_DSD	Age/sex: 20-24 Female	24,541
HTC_TST_DSD	Age/sex: 25-49 Female	41,395
HTC_TST_DSD	Age/sex: 50+ Female	9,013
HTC_TST_DSD	Sum of Age/Sex disaggregates	154,369
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	787
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	646
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	1,237
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	2,836
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	577
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	852
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	708
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	1,238
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	3,204
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	764
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	5,283
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	63,431
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	6,273
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	82,518
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	11,556



HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	145,949
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	157,505
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	1,499
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	5,296
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	1,551
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	5,905
HTC_TST_DSD	Test Result by Age: Positive: <1	182
HTC_TST_DSD	Test Result by Age: Positive: 1-9	1,246
HTC_TST_DSD	Age/sex: <1	783
HTC_TST_DSD	Age/sex: 1-9	2,518
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	1,804
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	12,736
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	8,687
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	662
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	2,620
HTC_TST_DSD	Service Delivery Point (Facility): VCT	9,373
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	6,711
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	287
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	300
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	533,146
HTC_TST_TA	Age/sex: 10-14 Male	57,074
HTC_TST_TA	Age/sex: 15-19 Male	25,892
HTC_TST_TA	Age/sex: 20-24 Male	31,116
HTC_TST_TA	Age/sex: 25-49 Male	72,053
HTC_TST_TA	Age/sex: 50+ Male	15,960
HTC_TST_TA	Age/sex: 10-14 Female	62,181



HTC_TST_TA	Age/sex: 15-19 Female	33,020
HTC_TST_TA	Age/sex: 20-24 Female	35,893
HTC_TST_TA	Age/sex: 25-49 Female	81,978
HTC_TST_TA	Age/sex: 50+ Female	18,461
HTC_TST_TA	Sum of Age/Sex disaggregates	433,628
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Male	2,468
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Male	2,130
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Male	2,540
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Male	5,462
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Male	1,508
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Female	2,694
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Female	2,360
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Female	2,974
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Female	7,388
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Female	1,756
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	72,776
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	105,465
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	79,967
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	119,677
HTC_TST_TA	Sum of Aggregated Age/Sex <15	152,743
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	225,142
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	377,885
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	3,153
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	8,130
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	3,439
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+	10,803



	Female	
HTC_TST_TA	Test Result by Age: Positive: <1	570
HTC_TST_TA	Test Result by Age: Positive: 1-9	3,894
HTC_TST_TA	Age/sex: <1	13,754
HTC_TST_TA	Age/sex: 1-9	90,366
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	14,929
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	163,191
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	117,668
HTC_TST_TA	Service Delivery Point (Facility): Malnutrition facilities	6,338
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	29,983
HTC_TST_TA	Service Delivery Point (Facility): VCT	111,445
HTC_TST_TA	Service Delivery Point (Facility): VMMC	5
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	85,647
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	2,541
HTC_TST_TA	Service Delivery Point (Facility): Index testing	3,231
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	10,442
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	10,618
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	466
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,423
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	516
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,386
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART	5,642



	during TB treatment during the reporting period	
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	7,051
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	218
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,638
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	219
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,748
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	492,297
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	11,171
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	99,715
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	11,027
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	209,219
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	128,607
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	68,038
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	57,737
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	1,246



TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	8,297
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	13,189
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	3,448
PMTCT_EID_TA	Sum of Infant Age disaggregates	16,637
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	228
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	186
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	76,056
TX_CURR_DSD	Age/Sex: 15-19 Male	591
TX_CURR_DSD	Age/Sex: 15-19 Female	2,751
TX_CURR_DSD	Sum of age/sex disaggregates	3,342
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	34
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	24,414
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	32
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	51,576
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	66
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	75,990
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	76,056
TX_CURR_DSD	Age/Sex: <1	3
TX_CURR_DSD	Age/Sex: <1-9	45
TX_CURR_DSD	Age/Sex: 10-14 Male	4
TX_CURR_DSD	Age/Sex: 10-14 Female	3
TX_CURR_DSD	Age/Sex: 20-24 Male	1,106
TX_CURR_DSD	Age/Sex: 25-49 Male	19,336
TX_CURR_DSD	Age/Sex: 50+ Male	3,388
TX_CURR_DSD	Age/Sex: 20-24 Female	7,308
TX_CURR_DSD	Age/Sex: 25-49 Female	37,723
TX_CURR_DSD	Age/Sex: 50+ Female	3,798



TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	507,287
TX_CURR_TA	Age/Sex: 15-19 Male	3,546
TX_CURR_TA	Age/Sex: 15-19 Female	16,266
TX_CURR_TA	Sum of Age/Sex disaggregations	19,812
TX_CURR_TA	Aggregated Age/Sex: <15 Male	28,779
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	140,222
TX_CURR_TA	Aggregated Age/Sex: <15 Female	28,437
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	295,807
TX_CURR_TA	Sum of Aggregated Age/Sex <15	57,216
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	436,029
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	493,245
TX_CURR_TA	Age/Sex: <1	8,422
TX_CURR_TA	Age/Sex: 1-9	33,005
TX_CURR_TA	Age/Sex: 10-14 Male	8,757
TX_CURR_TA	Age/Sex: 10-14 Female	8,400
TX_CURR_TA	Age/Sex: 20-24 Male	6,475
TX_CURR_TA	Age/Sex: 25-49 Male	114,396
TX_CURR_TA	Age/Sex: 50+ Male	20,017
TX_CURR_TA	Age/Sex: 20-24 Female	43,235
TX_CURR_TA	Age/Sex: 25-49 Female	222,858
TX_CURR_TA	Age/Sex: 50+ Female	22,292
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	64,953
TX_NEW_DSD	By Age/Sex: <1	604
TX_NEW_DSD	By Age/Sex: 1-9	2,367
TX_NEW_DSD	By Age/Sex: 10-14 Male	626
TX_NEW_DSD	By Age/Sex: 15-19 Male	477
TX_NEW_DSD	By Age/Sex: 20-24 Male	884
TX_NEW_DSD	By Age/Sex: 25-49 Male	15,474
TX_NEW_DSD	By Age/Sex: 50+ Male	2,698
TX_NEW_DSD	By Age/Sex: 10-14 Female	605



TX_NEW_DSD	By Age/Sex: 15-19 Female	2,201
TX_NEW_DSD	By Age/Sex: 20-24 Female	5,838
TX_NEW_DSD	By Age/Sex: 25-49 Female	30,166
TX_NEW_DSD	By Age/Sex: 50+ Female	3,013
TX_NEW_DSD	Sum of Age/Sex disaggregates	61,982
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	2,104
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	19,533
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	2,096
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	41,221
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	64,954
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	63,726
TX_NEW_TA	By Age/Sex: 1-9	4,155
TX_NEW_TA	By Age/Sex: 10-14 Male	1,103
TX_NEW_TA	By Age/Sex: 15-19 Male	445
TX_NEW_TA	By Age/Sex: 20-24 Male	822
TX_NEW_TA	By Age/Sex: 25-49 Male	14,320
TX_NEW_TA	By Age/Sex: 50+ Male	2,519
TX_NEW_TA	By Age/Sex: 10-14 Female	1,063
TX_NEW_TA	By Age/Sex: 15-19 Female	2,036
TX_NEW_TA	By Age/Sex: 20-24 Female	5,444
TX_NEW_TA	By Age/Sex: 25-49 Female	27,965
TX_NEW_TA	By Age/Sex: 50+ Female	2,799
TX_NEW_TA	Sum of Age/Sex disaggregates	58,516
TX_NEW_TA	Aggregated Grouping by Age: <1	1,061
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	3,270
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	15,722
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	3,241
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	33,173
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	55,406
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml)	74,937



	documented in the medical records and /or supporting laboratory results within the past 12 months.	
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	107,270
TX_PVLS_TA	Numerator: Indication: Routine	13,191
TX_PVLS_TA	Numerator: Indication: Targeted	61,745
TX_PVLS_TA	Denominator: Indication: Routine	17,980
TX_PVLS_TA	Denominator: Indication: Targeted	89,290
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	1,744
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	21,210
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	1,870
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	22,802
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	2,533
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	30,526
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	2,708
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	32,947
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	86,208
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	93,264
TX_RET_TA	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	66
TX_RET_TA	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,159
TX_RET_TA	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,322
TX_RET_TA	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12	1,199



	months after initiating ART)	
TX_RET_TA	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	504
TX_RET_TA	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	18,392
TX_RET_TA	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,780
TX_RET_TA	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,548
TX_RET_TA	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,416
TX_RET_TA	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,121
TX_RET_TA	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	38,048
TX_RET_TA	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11,653
TX_RET_TA	Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	72
TX_RET_TA	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,403



TX_RET_TA	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,429
TX_RET_TA	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,299
TX_RET_TA	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	549
TX_RET_TA	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	19,874
TX_RET_TA	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,340
TX_RET_TA	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,680
TX_RET_TA	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,542
TX_RET_TA	Age/Sex: 20-24 Female (Denominator: Total number of	2,344



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	41,198
TX_RET_TA	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12,584
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,919
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	26,868
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,179
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	53,242
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,179
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	29,062



	stopped ART, and those lost to follow-up)	
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,424
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	57,599

Implementing Mechanism Details

Mechanism ID: 13911	Mechanism Name: HIV Quality Improvement Project
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: New York AIDS Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information



Mechanism ID: 13911			
Mechanism Name: HIV Quality Improvement Project			
Prime Partner Name: New York AIDS Institute			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16515	Mechanism Name: Technical Assistance in Support of Clinical Training and Mentoring for HIV Treatment and Prevention Services
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: ITECH	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 13,029,528	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 13,029,528	
Funding Source	Funding Amount
GHP-State	13,029,528

Cross-Cutting Budget Attribution(s)

Human Resources for Health	7,482,593
Gender: Gender Equality	831,420
Focus Area:	Changing harmful gender norms and promoting positive gender norms



Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Motor Vehicles: Purchased	190,000

Budget Code Information

Mechanism ID:	16515		
Mechanism Name:	Technical Assistance in Support of Clinical Training and Mentoring for HIV Treatment and Prevention Services		
Prime Partner Name:	ITECH		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	335,289	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	438,489	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	3,256,262	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	433,371	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	7,476,333	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	1,089,784	0



Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	92,063
PMTCT_ART_TA	New on ART	6,416
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	8,510
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	92,063
PMTCT_STAT_TA	Number of new ANC and L&D clients	96,976
PMTCT_STAT_TA	By: Known positives at entry	8,753
PMTCT_STAT_TA	By: Number of new positives identified	8,644
PMTCT_STAT_TA	Sum of Positives Status disaggregates	17,397
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: <15	368
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 15-19	355
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 20-24	799
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: <15	357
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 15-19	355
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 20-24	789
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: <15	4,844
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 15-19	9,699
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator:	29,094



	20-24	
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 25-49	48,486
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 50+	4,843
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 25-49	6,132
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 50+	1,099
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 25-49	6,060
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 50+	1,083
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): <15	4,548
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 15-19	9,177
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 20-24	27,464
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 25-49	45,776
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 50+	4,564
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	488,043
HTC_TST_DSD	Age/sex: 10-14 Male	444
HTC_TST_DSD	Age/sex: 15-19 Male	416
HTC_TST_DSD	Age/sex: 20-24 Male	705
HTC_TST_DSD	Age/sex: 25-49 Male	11,539
HTC_TST_DSD	Age/sex: 50+ Male	2,549
HTC_TST_DSD	Age/sex: 10-14 Female	540
HTC_TST_DSD	Age/sex: 15-19 Female	801
HTC_TST_DSD	Age/sex: 20-24 Female	2,501
HTC_TST_DSD	Age/sex: 25-49 Female	20,300
HTC_TST_DSD	Age/sex: 50+ Female	2,650
HTC_TST_DSD	Sum of Age/Sex disaggregates	42,445
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	85



HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	41
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	70
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	1,145
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	253
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	105
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	80
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	248
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	2,012
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	263
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	35,338
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	131,924
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	36,868
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	232,084
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	72,206
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	364,008
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	436,214
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	2,110
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	12,604
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	2,201
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	22,222
HTC_TST_DSD	Test Result by Age: Positive: <1	28
HTC_TST_DSD	Test Result by Age: Positive: 1-9	293
HTC_TST_DSD	Age/sex: <1	765
HTC_TST_DSD	Age/sex: 1-9	8,614
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	37,748



HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	295,692
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	6,310
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	0
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	308
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	15,372
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	15,152
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	636,724
HTC_TST_TA	Age/sex: 10-14 Male	598
HTC_TST_TA	Age/sex: 15-19 Male	566
HTC_TST_TA	Age/sex: 20-24 Male	958
HTC_TST_TA	Age/sex: 25-49 Male	15,652
HTC_TST_TA	Age/sex: 50+ Male	3,459
HTC_TST_TA	Age/sex: 10-14 Female	733
HTC_TST_TA	Age/sex: 15-19 Female	1,086
HTC_TST_TA	Age/sex: 20-24 Female	3,394
HTC_TST_TA	Age/sex: 25-49 Female	27,541
HTC_TST_TA	Age/sex: 50+ Female	3,594
HTC_TST_TA	Sum of Age/Sex disaggregates	57,581
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Male	40
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Male	48
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Male	85
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Male	1,383
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Male	303
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Female	47
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Female	96
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Female	300
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Female	2,434
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Female	319
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	37,031



HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	172,662
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	36,676
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	326,282
HTC_TST_TA	Sum of Aggregated Age/Sex <15	73,707
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	498,944
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	572,651
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	2,280
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	18,070
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	2,373
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	34,500
HTC_TST_TA	Test Result by Age: Positive: <1	19
HTC_TST_TA	Test Result by Age: Positive: 1-9	137
HTC_TST_TA	Age/sex: <1	1,525
HTC_TST_TA	Age/sex: 1-9	4,500
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	47,661
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	428,996
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	69,250
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	88,452
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	2,211
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	7,255
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	7,405
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	222



TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	4,077
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	149
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,817
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	3,970
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	4,957
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	68
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2,217
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	44
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,642
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	363,805
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	11,087



TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	126,424
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	11,833
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	214,458
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	92,095
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	90,312
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	85,794
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	4,516
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	0
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	11,343
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	3,575
PMTCT_EID_TA	Sum of Infant Age disaggregates	14,918
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	208
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	153
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	70,723
TX_CURR_DSD	Age/Sex: 15-19 Male	40
TX_CURR_DSD	Age/Sex: 15-19 Female	74
TX_CURR_DSD	Sum of age/sex disaggregates	114
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	7,950
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	18,736
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	8,029
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	32,390
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	15,979
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	51,126
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	67,105



TX_CURR_DSD	Age/Sex: <1	8
TX_CURR_DSD	Age/Sex: <1-9	140
TX_CURR_DSD	Age/Sex: 10-14 Male	40
TX_CURR_DSD	Age/Sex: 10-14 Female	48
TX_CURR_DSD	Age/Sex: 20-24 Male	65
TX_CURR_DSD	Age/Sex: 25-49 Male	1,056
TX_CURR_DSD	Age/Sex: 50+ Male	234
TX_CURR_DSD	Age/Sex: 20-24 Female	229
TX_CURR_DSD	Age/Sex: 25-49 Female	1,861
TX_CURR_DSD	Age/Sex: 50+ Female	245
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	322,273
TX_CURR_TA	Age/Sex: 15-19 Male	231
TX_CURR_TA	Age/Sex: 15-19 Female	444
TX_CURR_TA	Sum of Age/Sex disaggregations	675
TX_CURR_TA	Aggregated Age/Sex: <15 Male	11,896
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	100,905
TX_CURR_TA	Aggregated Age/Sex: <15 Female	12,230
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	172,884
TX_CURR_TA	Sum of Aggregated Age/Sex <15	24,126
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	273,789
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	297,915
TX_CURR_TA	Age/Sex: <1	78
TX_CURR_TA	Age/Sex: 1-9	840
TX_CURR_TA	Age/Sex: 10-14 Male	245
TX_CURR_TA	Age/Sex: 10-14 Female	297
TX_CURR_TA	Age/Sex: 20-24 Male	389
TX_CURR_TA	Age/Sex: 25-49 Male	6,375
TX_CURR_TA	Age/Sex: 50+ Male	1,409
TX_CURR_TA	Age/Sex: 20-24 Female	1,381
TX_CURR_TA	Age/Sex: 25-49 Female	11,205
TX_CURR_TA	Age/Sex: 50+ Female	1,464



TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	67,827
TX_NEW_DSD	By Age/Sex: <1	67
TX_NEW_DSD	By Age/Sex: 1-9	713
TX_NEW_DSD	By Age/Sex: 10-14 Male	231
TX_NEW_DSD	By Age/Sex: 15-19 Male	298
TX_NEW_DSD	By Age/Sex: 20-24 Male	551
TX_NEW_DSD	By Age/Sex: 25-49 Male	7,351
TX_NEW_DSD	By Age/Sex: 50+ Male	1,571
TX_NEW_DSD	By Age/Sex: 10-14 Female	241
TX_NEW_DSD	By Age/Sex: 15-19 Female	555
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,851
TX_NEW_DSD	By Age/Sex: 25-49 Female	13,432
TX_NEW_DSD	By Age/Sex: 50+ Female	1,659
TX_NEW_DSD	Sum of Age/Sex disaggregates	27,740
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	2,756
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	12,628
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	2,825
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	21,098
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	39,307
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	41,691
TX_NEW_TA	By Age/Sex: 1-9	357
TX_NEW_TA	By Age/Sex: 10-14 Male	104
TX_NEW_TA	By Age/Sex: 15-19 Male	133
TX_NEW_TA	By Age/Sex: 20-24 Male	223
TX_NEW_TA	By Age/Sex: 25-49 Male	3,656
TX_NEW_TA	By Age/Sex: 50+ Male	808
TX_NEW_TA	By Age/Sex: 10-14 Female	126
TX_NEW_TA	By Age/Sex: 15-19 Female	0
TX_NEW_TA	By Age/Sex: 20-24 Female	0
TX_NEW_TA	By Age/Sex: 25-49 Female	0



TX_NEW_TA	By Age/Sex: 50+ Female	0
TX_NEW_TA	Sum of Age/Sex disaggregates	5,050
TX_NEW_TA	Aggregated Grouping by Age: <1	36
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	4,316
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	16,321
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	4,439
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	20,656
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	45,732
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	56,591
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	80,846
TX_PVLS_TA	Numerator: Indication: Routine	8,483
TX_PVLS_TA	Numerator: Indication: Targeted	33,734
TX_PVLS_TA	Denominator: Indication: Routine	12,131
TX_PVLS_TA	Denominator: Indication: Targeted	68,715
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	1,563
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	19,619
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	1,627
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	33,782
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	2,243
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	28,025
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	2,327
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	48,251
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	51,858
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	56,064



TX_RET_TA	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1
TX_RET_TA	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	37
TX_RET_TA	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5
TX_RET_TA	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	17
TX_RET_TA	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	65
TX_RET_TA	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	392
TX_RET_TA	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	86
TX_RET_TA	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5
TX_RET_TA	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	17
TX_RET_TA	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	125
TX_RET_TA	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	542
TX_RET_TA	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12	90



	months after initiating ART)	
TX_RET_TA	Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1
TX_RET_TA	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	39
TX_RET_TA	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	10
TX_RET_TA	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5
TX_RET_TA	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	71
TX_RET_TA	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	424
TX_RET_TA	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	91



TX_RET_TA	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	10
TX_RET_TA	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	23
TX_RET_TA	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	138
TX_RET_TA	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	586
TX_RET_TA	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	97
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,481
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	17,921
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,552
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number	29,522



	of adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,610
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	19,373
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,672
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	31,914

Implementing Mechanism Details

Mechanism ID: 16804	Mechanism Name: Scaling Up Voluntary Male Circumcision to Prevent HIV Transmission
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: ITECH	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 3,329,239	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 3,329,239	



Funding Source	Funding Amount
GHP-State	3,329,239

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	100,000
---------------------------	---------

Budget Code Information

Mechanism ID:	16804		
Mechanism Name:	Scaling Up Voluntary Male Circumcision to Prevent HIV Transmission		
Prime Partner Name:	ITECH		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	3,329,239	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	100,000
VMMC_CIRC_DSD	By Age: 0-60 days	0
VMMC_CIRC_DSD	By Age: 2 months - 9 years	0
VMMC_CIRC_DSD	By Age: 10-14	33,001
VMMC_CIRC_DSD	By Age: 15-19	40,000
VMMC_CIRC_DSD	By Age: 20-24	14,998
VMMC_CIRC_DSD	By Age: 25-29	6,998
VMMC_CIRC_DSD	By Age: 30-49	4,501
VMMC_CIRC_DSD	By Age: 50+	502



VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	88,501
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	100,000
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	60,000
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	40,000
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	0
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	0
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	0

Implementing Mechanism Details

Mechanism ID: 16806	Mechanism Name: Expansion of HIV care and prevention
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Zimbabwe Association of Church Hospitals	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,204,772	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,204,772	
Funding Source	Funding Amount
GHP-State	1,204,772

Cross-Cutting Budget Attribution(s)

Human Resources for Health	100,799
Gender: Gender Equality	67,197
Focus Area:	Changing harmful gender norms and promoting positive gender norms



Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research

Budget Code Information

Mechanism ID: 16806			
Mechanism Name: Expansion of HIV care and prevention			
Prime Partner Name: Zimbabwe Association of Church Hospitals			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	22,964	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	22,964	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	322,078	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	42,720	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	725,983	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	PDTX	68,063	0
-----------	------	--------	---

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	8,326
PMTCT_ART_TA	New on ART	632
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	949
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	8,326
PMTCT_STAT_TA	Number of new ANC and L&D clients	8,764
PMTCT_STAT_TA	By: Known positives at entry	1,169
PMTCT_STAT_TA	By: Number of new positives identified	779
PMTCT_STAT_TA	Sum of Positives Status disaggregates	1,948
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: <15	0
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 15-19	26
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 20-24	131
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: <15	0
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 15-19	17
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 20-24	87
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: <15	0
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 15-19	46



PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 20-24	229
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 25-49	550
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 50+	92
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 25-49	366
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 50+	0
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 25-49	244
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 50+	0
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): <15	0
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 15-19	44
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 20-24	218
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 25-49	523
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 50+	86
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	58,551
HTC_TST_DSD	Age/sex: 10-14 Male	92
HTC_TST_DSD	Age/sex: 15-19 Male	555
HTC_TST_DSD	Age/sex: 20-24 Male	693
HTC_TST_DSD	Age/sex: 25-49 Male	1,248
HTC_TST_DSD	Age/sex: 50+ Male	277
HTC_TST_DSD	Age/sex: 10-14 Female	97
HTC_TST_DSD	Age/sex: 15-19 Female	577
HTC_TST_DSD	Age/sex: 20-24 Female	722
HTC_TST_DSD	Age/sex: 25-49 Female	1,300
HTC_TST_DSD	Age/sex: 50+ Female	289
HTC_TST_DSD	Sum of Age/Sex disaggregates	5,850



HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	6
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	43
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	80
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	102
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	15
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	8
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	42
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	84
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	106
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	18
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	4,314
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	23,266
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4,545
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	26,426
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	8,859
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	49,692
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	58,551
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	408
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	2,058
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	451
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	2,215
HTC_TST_DSD	Test Result by Age: Positive: <1	8
HTC_TST_DSD	Test Result by Age: Positive: 1-9	49
HTC_TST_DSD	Age/sex: <1	63
HTC_TST_DSD	Age/sex: 1-9	377



HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	615
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	3,291
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	7,050
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	46,098
HTC_TST_DSD	Service Delivery Point (Facility): VCT	207
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	0
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	0
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	1,290
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	64,446
HTC_TST_TA	Age/sex: 10-14 Male	106
HTC_TST_TA	Age/sex: 15-19 Male	792
HTC_TST_TA	Age/sex: 20-24 Male	317
HTC_TST_TA	Age/sex: 25-49 Male	951
HTC_TST_TA	Age/sex: 50+ Male	211
HTC_TST_TA	Age/sex: 10-14 Female	146
HTC_TST_TA	Age/sex: 15-19 Female	1,094
HTC_TST_TA	Age/sex: 20-24 Female	438
HTC_TST_TA	Age/sex: 25-49 Female	1,313
HTC_TST_TA	Age/sex: 50+ Female	292
HTC_TST_TA	Sum of Age/Sex disaggregates	5,660
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Male	5
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Male	79
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Male	34
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Male	95
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Male	21
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Female	15
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Female	109
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Female	46



HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Female	131
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Female	29
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	5,284
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	24,732
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	5,733
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	28,697
HTC_TST_TA	Sum of Aggregated Age/Sex <15	11,017
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	53,429
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	64,446
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	411
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	2,173
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	464
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	2,580
HTC_TST_TA	Test Result by Age: Positive: <1	13
HTC_TST_TA	Test Result by Age: Positive: 1-9	52
HTC_TST_TA	Age/sex: <1	126
HTC_TST_TA	Age/sex: 1-9	504
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	3,947
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	27,861
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	9,366
HTC_TST_TA	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	3,623
HTC_TST_TA	Service Delivery Point (Facility): VCT	1,902
HTC_TST_TA	Service Delivery Point (Facility): VMMC	0
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	8,005



HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	1,497
HTC_TST_TA	Service Delivery Point (Facility): Index testing	8,245
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	752
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	767
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	53
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	312
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	54
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	333
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	419
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	524
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	27
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	175
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	28

	TB treatment during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	189
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	32,703
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	2,217
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	13,872
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	2,319
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	14,295
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	3,045
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	2,765
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	2,206
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	575
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	10
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	1,266
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	315
PMTCT_EID_TA	Sum of Infant Age disaggregates	1,581
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	166
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	40
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	6,122
TX_CURR_DSD	Age/Sex: 15-19 Male	386
TX_CURR_DSD	Age/Sex: 15-19 Female	359



TX_CURR_DSD	Sum of age/sex disaggregates	745
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	419
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	2,657
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	438
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	2,608
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	857
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	5,265
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	6,122
TX_CURR_DSD	Age/Sex: <1	124
TX_CURR_DSD	Age/Sex: <1-9	486
TX_CURR_DSD	Age/Sex: 10-14 Male	121
TX_CURR_DSD	Age/Sex: 10-14 Female	126
TX_CURR_DSD	Age/Sex: 20-24 Male	926
TX_CURR_DSD	Age/Sex: 25-49 Male	1,105
TX_CURR_DSD	Age/Sex: 50+ Male	240
TX_CURR_DSD	Age/Sex: 20-24 Female	910
TX_CURR_DSD	Age/Sex: 25-49 Female	1,098
TX_CURR_DSD	Age/Sex: 50+ Female	241
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	32,436
TX_CURR_TA	Age/Sex: 15-19 Male	1,501
TX_CURR_TA	Age/Sex: 15-19 Female	1,460
TX_CURR_TA	Sum of Age/Sex disaggregations	2,961
TX_CURR_TA	Aggregated Age/Sex: <15 Male	2,226
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	14,152
TX_CURR_TA	Aggregated Age/Sex: <15 Female	2,314
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	13,744
TX_CURR_TA	Sum of Aggregated Age/Sex <15	4,540
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	27,896
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	32,436
TX_CURR_TA	Age/Sex: <1	495
TX_CURR_TA	Age/Sex: 1-9	1,973



TX_CURR_TA	Age/Sex: 10-14 Male	482
TX_CURR_TA	Age/Sex: 10-14 Female	505
TX_CURR_TA	Age/Sex: 20-24 Male	3,780
TX_CURR_TA	Age/Sex: 25-49 Male	4,556
TX_CURR_TA	Age/Sex: 50+ Male	1,048
TX_CURR_TA	Age/Sex: 20-24 Female	3,625
TX_CURR_TA	Age/Sex: 25-49 Female	4,330
TX_CURR_TA	Age/Sex: 50+ Female	927
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	6,173
TX_NEW_DSD	By Age/Sex: <1	125
TX_NEW_DSD	By Age/Sex: 1-9	491
TX_NEW_DSD	By Age/Sex: 10-14 Male	121
TX_NEW_DSD	By Age/Sex: 15-19 Male	388
TX_NEW_DSD	By Age/Sex: 20-24 Male	933
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,115
TX_NEW_DSD	By Age/Sex: 50+ Male	242
TX_NEW_DSD	By Age/Sex: 10-14 Female	127
TX_NEW_DSD	By Age/Sex: 15-19 Female	362
TX_NEW_DSD	By Age/Sex: 20-24 Female	917
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,109
TX_NEW_DSD	By Age/Sex: 50+ Female	243
TX_NEW_DSD	Sum of Age/Sex disaggregates	5,557
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	422
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	2,678
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	442
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,631
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	6,173
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	4,458
TX_NEW_TA	By Age/Sex: 1-9	287
TX_NEW_TA	By Age/Sex: 10-14 Male	70



TX_NEW_TA	By Age/Sex: 15-19 Male	222
TX_NEW_TA	By Age/Sex: 20-24 Male	539
TX_NEW_TA	By Age/Sex: 25-49 Male	721
TX_NEW_TA	By Age/Sex: 50+ Male	141
TX_NEW_TA	By Age/Sex: 10-14 Female	76
TX_NEW_TA	By Age/Sex: 15-19 Female	204
TX_NEW_TA	By Age/Sex: 20-24 Female	510
TX_NEW_TA	By Age/Sex: 25-49 Female	627
TX_NEW_TA	By Age/Sex: 50+ Female	131
TX_NEW_TA	Sum of Age/Sex disaggregates	3,241
TX_NEW_TA	Aggregated Grouping by Age: <1	71
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	303
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	1,986
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	321
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	1,848
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	4,458
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	5,072
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	7,244
TX_PVLS_TA	Numerator: Indication: Routine	3,902
TX_PVLS_TA	Numerator: Indication: Targeted	1,170
TX_PVLS_TA	Denominator: Indication: Routine	5,572
TX_PVLS_TA	Denominator: Indication: Targeted	1,672
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	348
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	2,139
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	358
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	2,227
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	496



TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	3,054
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	515
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	3,179
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	5,135
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	5,551
TX_RET_TA	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4
TX_RET_TA	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	14
TX_RET_TA	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3
TX_RET_TA	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10
TX_RET_TA	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	25
TX_RET_TA	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	30
TX_RET_TA	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5
TX_RET_TA	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3
TX_RET_TA	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10



	months after initiating ART)	
TX_RET_TA	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	26
TX_RET_TA	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	31
TX_RET_TA	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7
TX_RET_TA	Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4
TX_RET_TA	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	14
TX_RET_TA	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4
TX_RET_TA	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	11
TX_RET_TA	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	27



TX_RET_TA	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	32
TX_RET_TA	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6
TX_RET_TA	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4
TX_RET_TA	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	11
TX_RET_TA	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	28
TX_RET_TA	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	33
TX_RET_TA	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of	352



	adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,165
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	366
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,252
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	381
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,339
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	396
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,435

Implementing Mechanism Details

Mechanism ID: 17013	Mechanism Name: Department of State Public Affairs and Civil Society Support
Funding Agency: State/AF	Procurement Type: Grant



Prime Partner Name: Department of State/AF - Public Affairs Section	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 100,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 100,000	
Funding Source	Funding Amount
GHP-State	100,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17013		
Mechanism Name:	Department of State Public Affairs and Civil Society Support		
Prime Partner Name:	Department of State/AF - Public Affairs Section		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	25,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	25,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	50,000	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17015	Mechanism Name: Department of state Ambassador's Self-Help Fund
Funding Agency: State/AF	Procurement Type: Grant
Prime Partner Name: State/AF Ambassador's PEPFAR Small Grants Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 60,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 60,000	
Funding Source	Funding Amount
GHP-State	60,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17015		
Mechanism Name:	Department of state Ambassador's Self-Help Fund		
Prime Partner Name:	State/AF Ambassador's PEPFAR Small Grants Program		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	30,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVOP	30,000	0
------------	------	--------	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17475	Mechanism Name: Lab Support
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Association of Public Health Laboratories	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 2,500,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,500,000	
Funding Source	Funding Amount
GHP-State	2,500,000

Cross-Cutting Budget Attribution(s)

Human Resources for Health	275,300
Motor Vehicles: Purchased	228,000

Budget Code Information

Mechanism ID: 17475			
Mechanism Name: Lab Support			
Prime Partner Name: Association of Public Health Laboratories			
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	HTXS	2,500,000	0
-----------	------	-----------	---

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	0
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	0
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	6
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	6
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	6
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	3
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	3
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	3
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	6
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	6
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	6
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of	0



	laboratories that perform this testing	
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	0
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	5
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	5
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	5
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	0
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	0
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
LAB_PT_TA	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	68
LAB_PT_TA	CD4: Number of laboratories that participate in this PT program	85
LAB_PT_TA	CD4: Number of laboratories that perform this testing	85
LAB_PT_TA	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
LAB_PT_TA	Early infant diagnostics: Number of laboratories that participate in this PT program	0
LAB_PT_TA	Early infant diagnostics: Number of laboratories that perform this testing	0
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in	720



	this PT program	
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	810
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	1,864
LAB_PT_TA	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
LAB_PT_TA	HIV viral load: Number of laboratories that participate in this PT program	0
LAB_PT_TA	HIV viral load: Number of laboratories that perform this testing	0
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	0
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	0
LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	44
LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	55
LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	120
LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	0
LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	0

Implementing Mechanism Details



Mechanism ID: 17476	Mechanism Name: Strengthening the Human Resources Information System and Development of Open health Information Enterprise Architecture
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Zimbabwe	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 200,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 200,000	
Funding Source	Funding Amount
GHP-State	200,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17476		
Mechanism Name:	Strengthening the Human Resources Information System and Development of Open health Information Enterprise Architecture		
Prime Partner Name:	University of Zimbabwe		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	200,000	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17534	Mechanism Name: Mavambo Orphan Care (MOC)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Mavambo Orphan Care (MOC)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,042,059	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,042,059	
Funding Source	Funding Amount
GHP-State	1,042,059

Cross-Cutting Budget Attribution(s)

Human Resources for Health	102,476
Economic Strengthening	84,782
Education	204,963
Gender: GBV	4,658
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	4,658
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation



Sub Area:	Capacity building
-----------	-------------------

Budget Code Information

Mechanism ID: 17534			
Mechanism Name: Mavambo Orphan Care (MOC)			
Prime Partner Name: Mavambo Orphan Care (MOC)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,042,059	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	65,128
OVC_SERV_DSD	Age/Sex: 18+ Male	1,308
OVC_SERV_DSD	Age/Sex: 18+ Female	12,024
OVC_SERV_DSD	Sum of Age/Sex disaggregates	13,332
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	993
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	440
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	89
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	944
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	390
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	68



	and sex: Education Support Male 18-24	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	511
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	8,510
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	86
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	644
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	511
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	8,510
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	86
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	644
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female <1	664
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	14,460
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	7,984
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	577
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	4,696
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male <1	619
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	12,145
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	6,504
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	354



	and sex: Other Services Male 18-24	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	329
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	1,821
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 1-9	7,996
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	24,194
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	27,602
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	2,024
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9	8,800

Implementing Mechanism Details

Mechanism ID: 17541	Mechanism Name: FACT Children Tariro
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Family AIDS Care Trust (FACT) Mutare	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 2,487,519	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,487,519	
Funding Source	Funding Amount
GHP-State	2,487,519

Cross-Cutting Budget Attribution(s)

Economic Strengthening	227,558
Education	419,694
Gender: GBV	120,073



Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	11,119
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building

Budget Code Information

Mechanism ID: 17541			
Mechanism Name: FACT Children Tariro			
Prime Partner Name: Family AIDS Care Trust (FACT) Mutare			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	2,487,519	0

Implementing Mechanism Indicator Information



Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	155,649
OVC_SERV_DSD	Age/Sex: 18+ Male	10,893
OVC_SERV_DSD	Age/Sex: 18+ Female	12,452
OVC_SERV_DSD	Sum of Age/Sex disaggregates	23,345
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	1,113
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	2,080
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	540
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	1,072
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	669
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	0



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	6,756
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	4,770
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+	0



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	2,534
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	6,756
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	1,244
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	4,770
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female <1	3,298
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	19,786
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	14,279
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male <1	3,398
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	19,786



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	13,192
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	1,204
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-9	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Male 1-9	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-9	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 1-9	19,786
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	66,152
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	66,152
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	1,205
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-9	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Female 1-9	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-9	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9	19,787

Implementing Mechanism Details

Mechanism ID: 17546	Mechanism Name: HOSPAZ Bantawana
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Hospice and Palliative Care Association of Zimbabwe	
Agreement Start Date: Redacted	Agreement End Date: Redacted

Approved



TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,042,059	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,042,059	
Funding Source	Funding Amount
GHP-State	1,042,059

Cross-Cutting Budget Attribution(s)

Human Resources for Health	139,751
Economic Strengthening	107,134
Education	279,491
Gender: GBV	127,134
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	2,793
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation



Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Budget Code Information

Mechanism ID:	17546		
Mechanism Name:	HOSPAZ Bantawana		
Prime Partner Name:	Hospice and Palliative Care Association of Zimbabwe		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,042,059	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	65,128
OVC_SERV_DSD	Age/Sex: 18+ Male	3,578
OVC_SERV_DSD	Age/Sex: 18+ Female	7,277
OVC_SERV_DSD	Sum of Age/Sex disaggregates	10,855
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	715
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	238
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	655
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	214
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	120



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	8,453
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	51
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	2,232
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	120
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	8,453
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	51
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	2,232
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	14,945
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	810
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	14,449
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	412
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	569
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 1-9	17,197
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	26,594
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	27,679
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	607
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9	16,694

Implementing Mechanism Details



Mechanism ID: 17578	Mechanism Name: HIV Community Care and Treatment
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 5,558,697	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 5,558,697	
Funding Source	Funding Amount
GHP-State	5,558,697

Cross-Cutting Budget Attribution(s)

Human Resources for Health	837,797
Motor Vehicles: Purchased	420,000
Gender: Gender Equality	670,219
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Capacity building
Condom programming	335,110

Budget Code Information

Mechanism ID: 17578			
Mechanism Name: HIV Community Care and Treatment			
Prime Partner Name: FHI 360			
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HBHC	135,369	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	135,368	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,660,725	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	3,446,744	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	180,491	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	147,441
HTC_TST_DSD	Age/sex: 10-14 Male	6,325
HTC_TST_DSD	Age/sex: 15-19 Male	2,049
HTC_TST_DSD	Age/sex: 20-24 Male	2,647
HTC_TST_DSD	Age/sex: 25-49 Male	7,022
HTC_TST_DSD	Age/sex: 50+ Male	1,355
HTC_TST_DSD	Age/sex: 10-14 Female	2,873
HTC_TST_DSD	Age/sex: 15-19 Female	4,871
HTC_TST_DSD	Age/sex: 20-24 Female	7,244
HTC_TST_DSD	Age/sex: 25-49 Female	15,468
HTC_TST_DSD	Age/sex: 50+ Female	2,085
HTC_TST_DSD	Sum of Age/Sex disaggregates	51,939
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	474



HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	238
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	307
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	814
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	157
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	216
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	566
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	840
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	1,794
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	241
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	22,051
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	31,704
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	19,341
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	74,345
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	41,392
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	106,049
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	147,441
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	1,652
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	3,678
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	1,450
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	8,629
HTC_TST_DSD	Test Result by Age: Positive: <1	170
HTC_TST_DSD	Test Result by Age: Positive: 1-9	557
HTC_TST_DSD	Age/sex: <1	2,264
HTC_TST_DSD	Age/sex: 1-9	7,436
HTC_TST_DSD	Service Delivery Point (Community): Index testing	125,325

Approved



HTC_TST_DSD	Service Delivery Point (Community): Other	22,116
-------------	---	--------

Implementing Mechanism Details

Mechanism ID: 17771	Mechanism Name: Challenge TB
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: International Union Against TB and Lung Disease	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-USAID	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17771		
Mechanism Name:	Challenge TB		
Prime Partner Name:	International Union Against TB and Lung Disease		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 17882	Mechanism Name: RTI Follow-on
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Research Triangle International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 858,289	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 858,289	
Funding Source	Funding Amount
GHP-State	858,289

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17882		
Mechanism Name:	RTI Follow-on		
Prime Partner Name:	Research Triangle International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	214,572	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	326,150	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	PDTX	317,567	0
-----------	------	---------	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17883	Mechanism Name: SEAM Follow-On
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: International Center for AIDS Care and Treatment Programs, Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 650,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 650,000	
Funding Source	Funding Amount
GHP-State	650,000

Cross-Cutting Budget Attribution(s)

Human Resources for Health	237,185
----------------------------	---------

Budget Code Information

Mechanism ID:	17883
Mechanism Name:	SEAM Follow-On
Prime Partner Name:	International Center for AIDS Care and Treatment Programs, Columbia University



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	125,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	125,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17884	Mechanism Name: Quality Improvement Capacity for Impact Project (QICIP)
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: Health Research Inc./New York State Department of Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 525,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 525,000	
Funding Source	Funding Amount
GHP-State	525,000

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID:	17884		
Mechanism Name:	Quality Improvement Capacity for Impact Project (QICIP)		
Prime Partner Name:	Health Research Inc./New York State Department of Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	125,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17885	Mechanism Name: BRTI Follow-on
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Biomedical Research and Training Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 500,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 500,000	
Funding Source	Funding Amount
GHP-State	500,000

Cross-Cutting Budget Attribution(s)



Gender: Gender Equality	14,380
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation

Budget Code Information

Mechanism ID: 17885			
Mechanism Name: BRTI Follow-on			
Prime Partner Name: Biomedical Research and Training Institute			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	500,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17887	Mechanism Name: AIDS Free EGPAF
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: John Snow Inc (JSI)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	



Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17887			
Mechanism Name: AIDS Free EGPAF			
Prime Partner Name: John Snow Inc (JSI)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18138	Mechanism Name: Building Local Capacity
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 63,403	
--	--



Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 63,403	
Funding Source	Funding Amount
GHP-State	63,403

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18138		
Mechanism Name:	Building Local Capacity		
Prime Partner Name:	Management Sciences for Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	63,403	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	21,973
HTC_TST_TA	Age/sex: 10-14 Male	0
HTC_TST_TA	Age/sex: 15-19 Male	0
HTC_TST_TA	Age/sex: 20-24 Male	0
HTC_TST_TA	Age/sex: 25-49 Male	0
HTC_TST_TA	Age/sex: 50+ Male	0
HTC_TST_TA	Age/sex: 10-14 Female	0
HTC_TST_TA	Age/sex: 15-19 Female	6,481



HTC_TST_TA	Age/sex: 20-24 Female	15,492
HTC_TST_TA	Age/sex: 25-49 Female	0
HTC_TST_TA	Age/sex: 50+ Female	0
HTC_TST_TA	Sum of Age/Sex disaggregates	21,973
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Male	0
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Male	0
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Male	0
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Male	0
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Male	0
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Female	0
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Female	680
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Female	1,647
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Female	0
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Female	0
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	0
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	21,973
HTC_TST_TA	Sum of Aggregated Age/Sex <15	0
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	21,973
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	21,973
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	0
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	0
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	0
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	2,327



HTC_TST_TA	Test Result by Age: Positive: <1	0
HTC_TST_TA	Test Result by Age: Positive: 1-9	0
HTC_TST_TA	Age/sex: <1	0
HTC_TST_TA	Age/sex: 1-9	0
HTC_TST_TA	Service Delivery Point (Community): Index testing	0
HTC_TST_TA	Service Delivery Point (Community): Homebased testing	0
HTC_TST_TA	Service Delivery Point (Community): Mobile testing	0
HTC_TST_TA	Service Delivery Point (Community): Other	21,973

Implementing Mechanism Details

Mechanism ID: 18139	Mechanism Name: Youth4Zero and Prevention+
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Southern Africa HIV and AIDS Information Dissemination Service (SAfAIDS)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18139



Mechanism Name: Youth4Zero and Prevention+			
Prime Partner Name: Southern Africa HIV and AIDS Information Dissemination Service (SAfAIDS)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	83,053
PP_PREV_DSD	Total number of people in the target population	243,224
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	83,053

Implementing Mechanism Details

Mechanism ID: 18141	Mechanism Name: Social Protection Fund
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: UNICEF	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID:	18141		
Mechanism Name:	Social Protection Fund		
Prime Partner Name:	UNICEF		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	6,848
OVC_SERV_DSD	Age/Sex: 18+ Female	761
OVC_SERV_DSD	Sum of Age/Sex disaggregates	761
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	3,804
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	2,283
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	761
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	6,087

Implementing Mechanism Details

Mechanism ID: 18151	Mechanism Name: EGPAF Central
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted

Approved



TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 538,906	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 538,906	
Funding Source	Funding Amount
GHP-State	538,906

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18151		
Mechanism Name:	EGPAF Central		
Prime Partner Name:	Elizabeth Glaser Pediatric AIDS Foundation		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	91,980	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	291,893	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	155,033	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 18174	Mechanism Name: Public Affairs Communications
Funding Agency: State/AF	Procurement Type: Grant
Prime Partner Name: Department of State/AF - Public Affairs Section	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 50,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 50,000	
Funding Source	Funding Amount
GHP-State	50,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18174		
Mechanism Name:	Public Affairs Communications		
Prime Partner Name:	Department of State/AF - Public Affairs Section		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	10,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	40,000	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18286	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18353	Mechanism Name: Global Health Supply Chain Program (GHSCP)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 31,502,137	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 31,502,137	
Funding Source	Funding Amount
GHP-State	31,502,137

Cross-Cutting Budget Attribution(s)

Human Resources for Health	2,042,889
Motor Vehicles: Purchased	1,400,000

Budget Code Information



Mechanism ID: 18353			
Mechanism Name: Global Health Supply Chain Program (GHSCP)			
Prime Partner Name: Global Health Supply Chain Program			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	2,000,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	135,200	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	501,062	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	2,193,600	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	21,971,822	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	4,700,453	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
INVS_COMD	Number of HIV Viral Load Reagents purchased	214,000
INVS_COMD	Number of HIV ARVs purchased	192,989
INVS_COMD	HIV Viral Load: Dollars planned (COP)/ spent (Actual)	3,000,000

Agency Information - Costs of Doing Business U.S. Agency for International Development

Agency Cost	GAP	GHP-State	GHP-USAID	Applied	Total	Total All
-------------	-----	-----------	-----------	---------	-------	-----------



of Doing Business				Pipeline		Cost of Doing Business Categories and Applied Pipeline Amount
Computers/IT Services		132,720	35,280	0	168,000	168,000
ICASS		616,200	163,800	0	780,000	780,000
Institutional Contractors		350,782	73,500	0	424,282	424,282
Non-ICASS Administrative Costs		573,309	152,398	0	725,707	725,707
Staff Program Travel		401,093	126,556	0	527,649	527,649
USG Staff Salaries and Benefits - Internationally Recruited		649,410	469,067	0	1,118,477	1,118,477
USG Staff Salaries and Benefits - Locally Recruited		1,115,176		0	1,115,176	1,115,176
Total	0	3,838,690	1,020,601	0	4,859,291	4,859,291

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost	GAP	GHP-State	GHP-USAID	Applied	Total	Total All
-------------	-----	-----------	-----------	---------	-------	-----------



of Doing Business				Pipeline		Cost of Doing Business Categories and Applied Pipeline Amount
Capital Security Cost Sharing		800,000		0	800,000	800,000
Computers/IT Services		114,234		0	114,234	114,234
ICASS		1,328,346		0	1,328,346	1,328,346
Management Meetings/Professional Development		181,000		0	181,000	181,000
Non-ICASS Administrative Costs		349,541		0	349,541	349,541
Staff Program Travel		202,000		0	202,000	202,000
USG Staff Salaries and Benefits - Internationally Recruited		2,077,000		0	2,077,000	2,077,000
USG Staff Salaries and Benefits - Locally Recruited	1,250,000	768,858		0	2,018,858	2,018,858
Total	1,250,000	5,820,979	0	0	7,070,979	7,070,979



U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Staff Program Travel		15,000		0	15,000	15,000
USG Staff Salaries and Benefits - Locally Recruited		57,000		0	57,000	57,000
Total	0	72,000	0	0	72,000	72,000